zerit 1mgml oral solution
bristol-myers squibb pharmaceuticals ltd - stavudine - oral solution - 1mg/1ml
zerit 40mg capsules
bristol-myers squibb pharmaceuticals ltd - stavudine - capsule - 40mg
opdivo 40mg4ml concentrate for solution for infusion vials
bristol-myers squibb pharmaceuticals ltd - nivolumab - solution for infusion - 10mg/1ml
opdivo 100mg10ml concentrate for solution for infusion vials
bristol-myers squibb pharmaceuticals ltd - nivolumab - solution for infusion - 10mg/1ml
coumadin- warfarin sodium tablet
bristol-myers squibb pharma company - warfarin sodium (unii: 6153cwm0cl) (warfarin - unii:5q7zvv76ei) - warfarin sodium 1 mg - coumadin® is indicated for: limitations of use coumadin has no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae. coumadin is contraindicated in: • pregnancy coumadin is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism [see warnings and precautions (5.7) and use in specific populations (8.1)] . coumadin can cause fetal harm when administered to a pregnant woman. coumadin exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. if coumadin is used during pregnancy or if the patient becomes pregn
sotyktu
bristol-myers squibb pharma eeig - deucravacitinib - psoriasis - immunosuppressants - treatment of moderate-to-severe plaque psoriasis in adults.
opdualag
bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanoma - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.
baraclude
bristol-myers squibb pharma eeig - entecavir - hepatitis b, chronic - antivirals for systemic use - baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with:compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active inflammation and/or fibrosis;decompensated liver disease.for both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with hbeag positive and hbeag negative hbv infection. with respect to patients with lamivudine-refractory hepatitis b.
camzyos
bristol-myers squibb pharma eeig - mavacamten - cardiomyopathy, hypertrophic - other cardiac preparations - treatment of symptomatic obstructive hypertrophic cardiomyopathy.
evotaz
bristol-myers squibb pharma eeig - cobicistat, atazanavir - hiv infections - antivirals for systemic use - evotaz is indicated in combination with other antiretroviral medicinal products for the treatment of hiv-1 infected adults and adolescents (aged 12 years and older weighing at least 35 kg) without known mutations associated with resistance to atazanavir (see sections 4.4 and 5.1).